Statens Serum Institut, Denmark.
Department of Pathology, Hvidovre Hospital, Denmark.
Sci Rep. 2017 Apr 7;7:45969. doi: 10.1038/srep45969.
There is a need for an improved vaccine for tuberculosis. ESAT-6 is a cardinal vaccine antigen with unique properties and is included in several vaccine candidates in development. ESAT-6 is also the core antigen in the IFN-γ release assays (IGRA) used to diagnose latent infection, rendering IGRA tests unspecific after vaccination. This challenge has prompted the development of a companion diagnostic for ESAT-6 based vaccines, an ESAT-6 free IGRA. We screened a panel of seven potential new diagnostic antigens not recognized in BCG vaccinated individuals. Three highly recognized antigens EspC, EspF and Rv2348c were identified and combined with CFP10 in an ESAT-6 free antigen cocktail. The cocktail was prepared in a field-friendly format, lyophilized with heparin in ready-to-use vacutainer tubes. The diagnostic performance of the ESAT-6 free IGRA was determined in a cross-validation study. Compared IGRA, the ESAT-6 free IGRA induced a comparable magnitude of IFN-γ release, and the diagnostic performance was on par with Quantiferon (sensitivity 84% vs 79%; specificity 99% vs 97%). The comparable performance of the ESAT-6 free IGRA to IGRA suggests potential as companion diagnostic for ESAT-6 containing vaccines and as adjunct test for latent infection.
需要改进结核病疫苗。ESAT-6 是一种主要的疫苗抗原,具有独特的特性,包含在几种正在开发的候选疫苗中。ESAT-6 也是用于诊断潜伏感染的 IFN-γ 释放检测(IGRA)中使用的核心抗原,使接种疫苗后的 IGRA 检测变得非特异性。这一挑战促使开发了一种基于 ESAT-6 的疫苗的伴随诊断方法,即 ESAT-6 无 IGRA。我们筛选了一组在卡介苗接种者中未识别的七种潜在新诊断抗原。确定了三种高度识别的抗原 EspC、EspF 和 Rv2348c,并与 CFP10 结合在一种 ESAT-6 无抗原混合物中。该混合物以一种适合野外使用的格式制备,用肝素冻干在即用型 vacutainer 管中。在一项交叉验证研究中确定了 ESAT-6 无 IGRA 的诊断性能。与 IGRA 相比,ESAT-6 无 IGRA 诱导的 IFN-γ 释放幅度相当,诊断性能与 Quantiferon 相当(敏感性 84%比 79%;特异性 99%比 97%)。ESAT-6 无 IGRA 与 IGRA 的相当性能表明其作为 ESAT-6 含疫苗的伴随诊断和潜伏感染的辅助检测具有潜在应用价值。